Cargando…

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy

PD-L1/PD-1 blockade immunotherapy has changed the therapeutic approaches for the treatment of many cancers. Nevertheless, the mechanisms underlying its efficacy or treatment failure are still unclear. Proficient systemic immunity seems to be a prerequisite for efficacy, as recently shown in patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Escors, David, Bocanegra, Ana, Chocarro, Luisa, Blanco, Ester, Piñeiro-Hermida, Sergio, Garnica, Maider, Fernandez-Rubio, Leticia, Vera, Ruth, Arasanz, Hugo, Kochan, Grazyna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655397/ https://www.ncbi.nlm.nih.gov/pubmed/36362027 http://dx.doi.org/10.3390/ijms232113241

Ejemplares similares

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy
por: Zuazo, Miren, et al.
Publicado: (2020)

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
por: Chocarro de Erauso, Luisa, et al.
Publicado: (2020)

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy
por: Zuazo, Miren, et al.
Publicado: (2020)

Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors
por: Blanco, Ester, et al.
Publicado: (2023)

Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor
por: Chocarro, Luisa, et al.
Publicado: (2022)

Cutting-Edge CAR Engineering: Beyond T Cells
por: Chocarro, Luisa, et al.
Publicado: (2022)

Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer
por: Arasanz, Hugo, et al.
Publicado: (2022)

Plasma fractalkine contributes to systemic myeloid diversity and PD‐L1/PD‐1 blockade in lung cancer
por: Bocanegra, Ana, et al.
Publicado: (2023)

CAR-T Cells for the Treatment of Lung Cancer
por: Chocarro, Luisa, et al.
Publicado: (2022)

Understanding LAG-3 Signaling
por: Chocarro, Luisa, et al.
Publicado: (2021)

Immune Profiling Uncovers Memory T-Cell Responses with a Th17 Signature in Cancer Patients with Previous SARS-CoV-2 Infection Followed by mRNA Vaccination
por: Echaide, Miriam, et al.
Publicado: (2022)

Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy
por: Zuazo, Miren, et al.
Publicado: (2019)

How Can We Improve the Vaccination Response in Older People? Part II: Targeting Immunosenescence of Adaptive Immunity Cells
por: Garnica, Maider, et al.
Publicado: (2022)

How Can We Improve Vaccination Response in Old People? Part I: Targeting Immunosenescence of Innate Immunity Cells
por: Aiello, Anna, et al.
Publicado: (2022)

The intracellular signalosome of PD-L1 in cancer cells
por: Escors, David, et al.
Publicado: (2018)

Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer
por: Arasanz, Hugo, et al.
Publicado: (2023)

PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer
por: Bocanegra, Ana, et al.
Publicado: (2019)

Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies
por: Hernandez, Carlos, et al.
Publicado: (2020)

PD1 signal transduction pathways in T cells
por: Arasanz, Hugo, et al.
Publicado: (2017)

Hyperprogressive Disease: Main Features and Key Controversies
por: Arasanz, Hugo, et al.
Publicado: (2021)

Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies
por: Arasanz, Hugo, et al.
Publicado: (2018)

mRNA Vaccines against SARS-CoV-2: Advantages and Caveats
por: Echaide, Miriam, et al.
Publicado: (2023)

Clinical landscape of LAG-3-targeted therapy
por: Chocarro, L., et al.
Publicado: (2022)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Profound Reprogramming towards Stemness in Pancreatic Cancer Cells as Adaptation to AKT Inhibition
por: Arasanz, Hugo, et al.
Publicado: (2020)

A Proteomic Atlas of Lineage and Cancer-Polarized Expression Modules in Myeloid Cells Modeling Immunosuppressive Tumor-Infiltrating Subsets
por: Blanco, Ester, et al.
Publicado: (2021)

Application of PD-1 Blockade in Cancer Immunotherapy
por: Wu, Xiaomo, et al.
Publicado: (2019)

Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics
por: Arasanz, Hugo, et al.
Publicado: (2020)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
por: Zhang, Min, et al.
Publicado: (2019)

The multi-specific V(H)-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity
por: Edwards, Carolyn J., et al.
Publicado: (2021)

Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade
por: Serganova, Inna, et al.
Publicado: (2016)

Systemic Anti–PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid
por: Portnow, Jana, et al.
Publicado: (2020)

Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
por: Yuan, Yu, et al.
Publicado: (2021)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Blockade of PD-1/PD-L1 Promotes Adoptive T-Cell Immunotherapy in a Tolerogenic Environment
por: Blake, Stephen J. P., et al.
Publicado: (2015)

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
por: Jia, Long, et al.
Publicado: (2018)

Immunotherapy of alveolar echinococcosis via PD‐1/PD‐L1 immune checkpoint blockade in mice
por: Wang, Junhua, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jck07g9k6l77f78ki8aqqnm3r9